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Objectives. This study was undertaken to define and better
understand the characteristics and outcomes of patients with
diabetes treated for acute myocardial infarction with contempo-
rary thrombolysis.
Background. Although thrombolysis has substantially im-
proved survival of patients with myocardial infarction, diabetes
mellitus remains an independent predictor for a poor prognosis.
Methods. We characterized the contemporary relation between
diabetes and outcome after myocardial infarction treated with
thrombolytic agents from a large international cohort. Of 41,021
patients randomized to receive accelerated tissue-type plasmino-
gen activator (t-PA), streptokinase or a combination of both
agents in the Global Utilization of Streptokinase and Tissue
Plasminogen Activator for Occluded Coronary Arteries study,
there were 5,944 patients with diabetes and 34,888 patients
without diabetes.
Results. Patients with diabetes were older and more likely to be
female, to present with anterior wall infarction, to receive throm-
bolysis later and to have triple-vessel coronary artery disease.
Mortality at 30 days was highest among diabetic patients treated
with insulin (12.5%) compared with non–insulin-treated diabetic
(9.7%) and nondiabetic (6.2%) patients (p < 0.001). Mortality was
lowest among those with diabetes receiving accelerated t-PA,
which is consistent with the results of the overall patient cohort.
Although stroke occurred more frequently among diabetic (1.9%)
than nondiabetic patients (1.4%, p < 0.001), there was no
significant difference in the rates of intracranial hemorrhage.
Cardiac failure, shock, atrioventricular block and atrial flutter/
fibrillation were more common among diabetic patients. The
proportion of patients undergoing revascularization was similar
between patients with and without diabetes, although diabetic
patients were more likely to undergo coronary artery bypass graft
surgery (10.4% vs. 8.3%). Diabetes remained an independent
predictor for mortality at 1-year follow-up (14.5% vs. 8.9%, p <
0.001).
Conclusions. Diabetes, alone and in association with its comor-
bidities, portends a substantially worse 30-day and 1-year prog-
nosis for patients with myocardial infarction.
(J Am Coll Cardiol 1997;30:171–9)
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Diabetes mellitus is an important and common medical con-
dition that is a major risk factor for the development of
atherosclerotic coronary disease. In a prospective 16-year
follow-up Framingham study of 239 patients with diabetes,
cardiovascular mortality was nearly three times that of the
general population (1). Among patients with an acute myocar-
dial infarction, 10% to 25% have diabetes mellitus (2,3).
Previous studies, in both the prethrombolytic (2,4–13) and
thrombolytic (14–16) eras, have shown that patients with
diabetes have considerably higher mortality and morbidity
rates than nondiabetic patients. Although patients with diabe-
tes are generally older (2,9,10,12–15), more frequently have
had a previous myocardial infarction (9,10,12) and have more
severe coronary artery disease (14) and worse left ventricular
ejection fractions (13,14), most studies concur that diabetes
mellitus is an independent predictor for mortality after a
myocardial infarction (2,12,13,17).
Thrombolytic agents unquestionably lower the mortality of
patients with an acute myocardial infarction, even among such
patients with diabetes (18,19). However, a recent study showed
that patients with diabetes were less likely to receive throm-
bolysis, despite having a greater potential for benefit (20). The
reasons for this are several and, in addition to the known
comorbidities, most likely include silent ischemia and late or
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atypical presentation. Indeed, a meta-analysis of several large
randomized trials found that thrombolysis saved 37 lives per
1,000 patients with diabetes, compared with 15 per 1,000
patients without diabetes at 35 days (21). Furthermore, no
outcome differences have been shown for patients with diabe-
tes among the various thrombolytic strategies (15,16). Accel-
erated administration of tissue-type plasminogen activator
(t-PA) provided earlier and more complete infarct-related
artery patency (22) and improved survival among 41,021
patients in the Global Utilization of Streptokinase and Tissue
Plasminogen Activator for Occluded Coronary Arteries
(GUSTO-I) trial, compared with other thrombolytic agents
(23). Given that patients with diabetes have increased platelet
aggregatory activity (24) and impaired fibrinolytic activity (25),
they may particularly benefit from such an accelerated throm-
bolytic regimen.
With this in mind, we analyzed the population of the
GUSTO-I trial, which prospectively identified insulin-treated
diabetic, non–insulin-treated diabetic or nondiabetic patients
to define more specifically the characteristics and outcomes of
patients with diabetes treated for an acute myocardial infarc-
tion.
Methods
Patient population. A total of 41,021 patients presenting
within 6 h of chest pain consistent with a myocardial infarction
and ST segment elevation were enrolled in the GUSTO-I trial
from December 27, 1990 to February 22, 1993. Data were
collected as to whether patients had a previous or current
diagnosis of diabetes, and if so, whether they were treated with
insulin injections. The specifics of study design, patient eligi-
bility, data collection and management and quality assurance
have been previously detailed (23).
Thrombolytic strategies. Patients were randomized to 1)
streptokinase, 1.5 million U over 60 min, with subcutaneous
heparin; 2) streptokinase, 1.5 million U over 60 min, with
intravenous heparin bolus and infusion, adjusting the dose to
maintain an activated partial thromboplastin time of (aPTT) of
60 to 85 s; 3) accelerated t-PA, 15-mg bolus and then infusion
of 0.75 mg/kg body weight (up to 50 mg) over 30 min and
0.5 mg/kg (up to 35 mg) over another 60 min, plus intravenous
heparin; or 4) the combination of intravenous t-PA (1.0 mg/kg
over 60 min) [up to 90 mg], with 10% administered as a bolus)
and streptokinase (1.0 million U over 60 min) infused through
separate catheters with intravenous heparin. Patients were to
receive chewable aspirin as soon as possible, followed by a
daily dose of 160 or 325 mg. Intravenous bolus injection of
10 mg of atenolol, in two divided doses, followed by a daily oral
dose of 50 to 100 mg, was also recommended for patients
without contraindications. The use of other medications, such
as nitrates, calcium channel blockers, angiotensin-converting
enzyme inhibitors and digitalis, coronary angiography and
revascularization procedures were at the discretion of the
attending physician.
End points. The primary end point was all-cause mortality
at 30 days. Other important clinical outcomes, including rein-
farction, stroke and bleeding, were also collected prospectively
at 30 days, and mortality was assessed at 1 year. The cause of
focal neurologic deficit was determined with the aid of com-
puted axial tomography, magnetic resonance imaging or post-
mortem examination, and classified as primary intracranial
hemorrhage, cerebral infarction with conversion to hemor-
rhage, nonhemorrhagic cerebral infarction or unknown (when
such examinations were not performed). The stroke data were
interpreted by an independent Stroke Review Committee that
had no knowledge of the treatment assignment. Bleeding was
classified as severe when it was intracerebral or resulted in
substantial hemodynamic compromise that required interven-
tion; moderate when blood transfusion alone was required; or
mild when no transfusion was required.
Coronary angiography and revascularization. Coronary
angiography was performed in patients during the in-hospital
period according to the protocol of the angiographic study and
at the discretion of the attending physicians. Among those who
underwent coronary angiography, a major epicardial vessel was
considered diseased if lumen diameter narrowing $50% was
present, with at least $70% stenosis (26). Left ventriculogra-
phy was performed in the right anterior oblique projection.
Statistical analysis. Demographic characteristics of pa-
tients with and without diabetes were compared using the
unpaired Student t test and Wilcoxon test for continuous
variables and the Pearson chi-square test for categoric vari-
ables. Continuous variables are described as the median and
interquartile range, and categoric variables are described as
the percentage of nonmissing data. Tests for synergism be-
tween diabetes and other single risk factors was performed
using the Breslow-Day test for homogeneity. Multiple risk
factors and possible interactions were considered using logistic
regression models. The cohort of all randomized patients and
the cohort of 30-day survivors were analyzed separately using
multivariable Cox regression analyses. Stepwise models,
including the statistically significant variables, and models
including a complete set of prespecified risk factors were
both fit. Kaplan-Meier product limit estimates and log-rank
tests were used for analysis of late death (with 1 SE for
1-year mortality).
Abbreviations and Acronyms
aPTT 5 activated partial thromboplastin time
CI 5 confidence interval
GUSTO-I 5 Global Utilization of Streptokinase and Tissue
Plasminogen Activator for Occluded Coronary
Arteries trial
OR 5 odds ratio
TAMI 5 Thrombolysis and Angioplasty in Myocardial
Infarction trial
TIMI 5 Thrombolysis in Myocardial Infarction trial
t-PA 5 tissue-type plasminogen activator
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Results
Baseline characteristics. Of the 41,021 patients enrolled
into the study, diabetic and insulin treatment status were
complete in 99.7% and 99.8%, respectively. This included
34,888 nondiabetic, 1,643 insulin-treated and 4,301 non–
insulin-treated diabetic patients. Patients with diabetes were
older, more frequently women, nonwhite, enrolled in the
United States and more likely to have a previous history of
vascular disease, anterior location of infarction and worse
Killip class at presentation (Table 1). In addition, patients with
diabetes presented, on average, ;15 min later for treatment
than nondiabetic patients. The diurnal variation regarding
onset of myocardial infarction was fairly similar among pa-
tients with and without diabetes mellitus, with a primary peak
at ;9 to 10 AM, and a secondary peak at ;2 to 3 PM. Similar
trends were also observed among insulin and non–insulin-
treated diabetic patients.
Study medications. A total of 5,796 (96.4%) patients with
diabetes and 33,871 (97.1%) patients without diabetes com-
pleted their assigned thrombolytic regimen. On admission,
aspirin was administered to 96.6% and 97.4% of patients with
and without diabetes, respectively, and in 80.2% and 78.7%
this dose was #160 mg. Nearly all patients (99.5%) who were
assigned to receive intravenous heparin, had an infusion for
24 h, and at least half achieved target therapeutic anticoagu-
lation. However, 11% of patients assigned to the subcutaneous
heparin group did not receive this therapy. Instead, 36% of
these patients received intravenous heparin, with recurrent
ischemia reported as the principal reason. An intravenous
beta-adrenergic blocking agent was administered to 45.7% and
44.2% of patients with and without diabetes, respectively. In
contrast, 68.5% of patients with diabetes received oral beta-
blockers, compared with 71.6% of patients without diabetes.
Major clinical outcomes. Thirty-day mortality (Tables 2 and
3). The 30-day mortality for patients with diabetes was signif-
icantly higher (10.5%) than that for nondiabetic patients
(6.2%) (odds ratio [OR] 1.77, 95% confidence interval [CI]
1.61 to 1.95). Moreover, patients with diabetes treated with
insulin had an even higher mortality (12.5%) than that of those
not treated with insulin (9.7%) (OR 1.32, 95% CI 1.10 to 1.57).
Duration of diabetes was not significantly associated with
30-day mortality after adjusting for other baseline characteris-
tics (p 5 0.687) (17). We also found that the mortality rates
associated with different thrombolytic regimens in patients
with and without diabetes mellitus were similar to the entire
cohort of patients in GUSTO-I, in that patients with diabetes
receiving accelerated t-PA had the lowest mortality (Fig. 1). As
with the overall patient cohort, several demographic features,
including older age ($65 years), female gender, hypertension
and a previous myocardial infarction, were found to be univa-
riable predictors for poor 30-day outcome among patients with
and without diabetes. However, adjusting for baseline risk
factors (17), the size of the effect for each of these demo-
graphic features was similar among patients with and without
diabetes.
Reinfarction (Tables 2 and 3). The reinfarction rate among
all patients was 4.0%, with little difference between diabetic
(4.3%) and nondiabetic patients (3.9%, p 5 0.145). There was
a trend (p 5 0.053) toward more reinfarctions among insulin-
treated diabetic patients receiving t-PA than among nondia-
betic patients, although no difference in reinfarction rates
between insulin-treated and non–insulin-treated diabetic pa-
tients was found.
Stroke (Tables 2 and 3). Strokes occurred overall in 1.4% of
patients in GUSTO-I. Compared with nondiabetic patients,
Table 1. Baseline Characteristics
Characteristics*
Nondiabetic
Patients
(n 5 34,888)
Diabetic Patients
Non–Insulin
Treated
(n 5 4,301)
Insulin
Treated
(n 5 1,643)
Demographics
Age (yr) 61 (51, 70) 64 (56, 71) 64 (56, 71)
Male (%) 77 68 57
White (%) 93 87 84
Weight (kg) 78 (69, 87) 81 (71, 92) 80 (70, 93)
Height (cm) 172 (165, 178) 170 (163, 177) 169 (162, 177)
Body mass index 26 (24, 29) 28 (25, 31) 28 (25, 32)
U.S. enrollment (%) 55 59 75
Risk factors
Hypertension (%) 35 54 55
Smoking (%)
Current 45 31 28
Former 26 31 31
Never 29 38 41
Hypercholesterolemia
(%)
34 63 35
Family history (%)† 42 43 42
Other history
Previous MI (%) 15 21 26
Previous angina (%) 36 43 44
Stoke (%) 2 3 4
Previous bypass
surgery (%)
4 5 7
Previous angioplasty (%) 4 5 6
Presenting characteristics
Systolic BP (mm Hg) 129 (112, 142) 130 (115, 150) 130 (113, 149)
Diastolic BP (mm Hg)‡ 80 (70, 90) 80 (70, 90) 77 (67, 87)
Heart rate (beats/min) 72 (62, 85) 77 (65, 90) 80 (68, 93)
Infarct location (%)
Anterior 38 43 44
Inferior 58 54 53
Other 3 3 3
Killip class (%)
I 86 82 78
II 12 14 17
III 1 3 3
IV 1 1 2
Peak CK (IU/liter) 1,445 (671, 2,690) 1,272 (557, 2,528) 1,302 (543, 2,551)
Symptom to treatment (h) 2.8 (2.0, 3.8) 3.0 (2.1, 4.3) 3.1 (2.2, 4.3)
Length of stay (days) 9 (7, 13) 9 (7, 14) 9 (7, 13)
*p , 0.001 for all characteristics for nondiabetic versus diabetic patients,
except as noted. †p 5 0.977. ‡p 5 0.070. Data presented are percent of patients
or median (25th, 75th percentile). BP 5 blood pressure; CK 5 creatine kinase;
MI 5 myocardial infarction.
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the risk for stroke was 42% higher (95% CI 15% to 74%)
among diabetic patients. The risk was greater for insulin-
treated diabetic patients (OR 1.59, 95% CI 1.07 to 2.36) than
for non–insulin-treated diabetic patients. Among patients with
diabetes, there was a trend toward a more frequent occurrence
of any stroke in patients treated with t-PA compared with
streptokinase (p 5 0.08). Importantly, among the different
categories of stroke, the occurrence of primary intracranial
hemorrhage and hemorrhagic conversion after cerebral infarc-
tion was not significantly different between patients with and
without diabetes (p 5 0.810).
Other complications (Table 4). Although bleeding compli-
cations were more common among patients with diabetes than
those without it, the majority of the events were categorized as
mild to moderate. Congestive heart failure, sustained hypoten-
sion, cardiogenic shock, atrial flutter or fibrillation, atrioven-
tricular block, ventricular fibrillation and asystole also oc-
curred significantly more frequently in patients with diabetes.
The length of hospital stay was similar between patients with
and without diabetes.
One-year mortality. The higher mortality among patients
with diabetes compared with those without it continued to
increase after 30 days. At 30 days, mortality among patients
with diabetes was ;40% higher than that among nondiabetics.
However, by the end of the first year, mortality rates were over
60% higher among patients with diabetes (14.5 6 0.5%) than
among nondiabetics (8.9 6 0.2%, p 5 0.0001) (Fig. 2). Indeed,
for survival after 30 days, an additional 4.3% of patients with
diabetes died compared with 2.7% of patients without diabe-
Figure 1. ORs and 95% CIs for 30-day mortality in patients with and
without diabetes. SK 5 streptokinase.
Table 2. Thirty-Day Outcomes and Diabetic Status
Outcome
Nondiabetic
Patients
(n 5 34,888)
Diabetic Patients
Non–Insulin
Treated
(n 5 4,301)
Insulin
Treated
(n 5 1,643)
Mortality* 2,163 (6.2) 417 (9.7) 206 (12.5)
Reinfarction† 1,366 (3.9) 182 (4.2) 75 (4.6)
Stroke* 477 (1.4) 70 (1.6) 44 (2.7)
Primary intracranial
hemorrhage
235 (0.7) 18 (0.4) 15 (0.9)
Hemorrhagic conversion 25 (0.1) 8 (0.2) 1 (0.1)
Nonhemorrhagic 180 (0.5) 38 (0.9) 28 (1.7)
Unknown 37 (0.1) 6 (0.1) 0 (0)
*p , 0.01, †p 5 0.145, patients with versus without diabetes. Data presented
are number (%) of patients.
Table 3. Thirty-Day Outcome According to Thrombolytic Strategy
Nondiabetic
Patients
Diabetic Patients
Non–Insulin
Treated
Insulin
Treated
t-PA n 5 8,865 n 5 1,079 n 5 412
Mortality* 504 (5.7) 86 (8.0) 51 (12.4)
Reinfarction§ 347 (3.9) 49 (4.5) 25 (6.1)
Stroke* 132 (1.5) 18 (1.7) 12 (2.9)
Streptokinase‡ n 5 17,143 n 5 2,181 n 5 824
Mortality* 1,100 (6.4) 222 (10.2) 114 (13.9)
Reinfarction 658 (3.9) 87 (4.5) 33 (4.0)
Stroke† 212 (1.2) 31 (1.4) 23 (2.8)
t-PA plus streptokinase n 5 8,880 n 5 1,041 n 5 407
Mortality* 559 (6.3) 111 (10.7) 41 (10.1)
Reinfarction 361 (4.1) 45 (4.3) 17 (4.2)
Stroke 138 (1.6) 22 (2.1) 10 (2.5)
*p , 0.001, †p 5 0.017, patients with versus without diabetes. §p 5 0.053,
insulin-treated diabetic versus nondiabetic patients. ‡Pooled streptokinase study
arms. Data presented are number (%) of patients. t-PA 5 tissue-type plasmin-
ogen activator.
Table 4. Other Clinical Outcomes at 30 Days
Outcome
Nondiabetic
Patients
(n 5 34,888)
Diabetic Patients
Non-Insulin
Treated
(n 5 4,301)
Insulin
Treated
(n 5 1,643)
Congestive heart failure 5,277 (15) 872 (20) 448 (27)
Sustained hypotension 4,042 (12) 529 (12) 256 (16)
Cardiogenic shock 1,971 (6) 301 (7) 135 (8)
Atrial flutter/fibrillation 3,146 (9) 483 (11) 188 (12)
Atrioventricular block*† 2,816 (8) 363 (9) 176 (11)
Sustained ventricular
tachycardia‡
2,129 (6) 264 (6) 119 (7)
Ventricular fibrillation‡ 2,325 (7) 276 (6) 116 (7)
Asystole 1,828 (5) 314 (7) 160 (10)
Recurrent ischemia 6,802 (20) 932 (22) 380 (23)
Bleeding
Moderate 3,871 (11) 523 (12) 252 (15)
Severe‡ 420 (1) 52 (1) 22 (1)
Any complication§ 17,971 (52) 2,382 (55) 983 60)
Angioplasty\ 7,679 (22) 888 (21) 336 (21)
Bypass surgery 2,903 (8) 436 (10) 183 (11)
Any revascularization‡ 10,254 (29) 1,284 (30) 502 (31)
p , 0.001 for all outcomes, patients with versus without diabetes, except as
noted. *Second- or third-degree heart block. †p 5 0.006. ‡p . 0.05. §Any
complication includes the occurrence of at least one of the following events:
death, stroke, reinfarction, heart failure, sustained hypotension, cardiogenic
shock, tachyarrhythmias and bradyarrhythmias, recurrent ischemia and bleeding.
\p 5 0.014. Data presented are number (%) of patients.
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tes. Multivariable models show that diabetes remained an
independent predictor of mortality throughout the first year of
follow-up. Likewise, the higher mortality among insulin-
treated diabetic patients (17.8 6 1.0%) than among non–
insulin-treated diabetic patients (13.1 6 0.5%) remained evi-
dent (p 5 0.0001).
Coronary angiography and revascularization (Tables 4 and 5).
Coronary angiography was performed in 21,503 patients in the
GUSTO population, and patients with diabetes were more
likely to have multivessel coronary artery disease than nondia-
betics (OR 1.68, 95% CI 1.56 to 1.82). Patients treated with
insulin had a marginally higher incidence of multivessel coro-
nary artery disease compared with non–insulin-treated patients
(OR 1.21, 95% CI 1.00 to 1.47). The median left ventricular
ejection fraction was 50% and 52% among patients with and
without diabetes, respectively, and the overall rates of revas-
cularization were similar. Of note, patients with diabetes were
more likely to undergo coronary artery bypass graft surgery
compared with patients without diabetes. This observation may
be attributed, at least in part, to the higher proportion of
patients with left main coronary artery or triple-vessel disease
among those with (35%) versus without diabetes (24%). In the
GUSTO-I population, ;35% of patients with triple-vessel
coronary artery disease subsequently underwent bypass sur-
gery regardless of diabetic status.
Discussion
Among the 41,021 patients of the GUSTO-I cohort, 30-day
and 1-year mortality and the rates of stroke, recurrent infarc-
tion, recurrent ischemia, heart failure, sustained hypotension,
cardiogenic shock, atrial flutter or fibrillation, atrioventricular
block and asystole were consistently higher among patients
with than without diabetes. Our study was limited to patients
presenting within 6 h from the onset of symptoms and receiv-
ing thrombolytic therapy. Nonetheless, the improved survival
with accelerated t-PA versus the other thrombolytic regimens,
which was seen in the overall GUSTO-I population, was also
observed among patients with diabetes, especially among those
not treated with insulin.
Consistent with previous studies (14–16), our patients with
diabetes were older, more frequently female, less often smok-
ers, more commonly had anterior wall infarction, received
thrombolytic therapy ;20 min later and more likely to have
triple-vessel coronary artery disease than patients without
diabetes. Although it is uncertain why patients with diabetes
present later than patients without diabetes, the impaired
sensation of myocardial ischemic pain among patients with
diabetes may contribute to this finding (27,28). However,
unlike some studies (29,30) that suggest that the circadian
distribution of the onset of myocardial infarction was altered
among patients with diabetes, the relation between morning
and evening peaks were preserved among our patients, corrob-
Figure 2. Kaplan-Meier estimates of cumula-
tive mortality by diabetic status.
Table 5. Coronary Angiographic Findings
Nondiabetic
Patients
Diabetic Patients
Non–Insulin
Treated
Insulin
Treated
Extent of disease* n 5 14,671 n 5 1,775 n 5 739
None† 1,714 (11.7) 138 (7.8) 66 (8.9)
Single 5,296 (36.1) 476 (26.8) 159 (21.5)
Double 4,167 (28.4) 570 (32.1) 230 (31.1)
Triple 3,133 (21.4) 544 (30.7) 253 (34.2)
LMCA 361 (2.5) 47 (2.7) 31 (4.1)
Ejection fraction* n 5 13,581 n 5 1,667 n 5 649
Percent 52 (44, 60) 50 (40, 60) 50 (40, 60)
*p , 0.001, patients with versus without diabetes. †A major epicardial
coronary vessel was diseased if the degree of stenosis was $50% and at least one
vessel had a degree of stenosis $70%. Data presented are number (%) of
patients or median (25th, 75th percentile). LMCA 5 left main coronary artery.
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orating the results of the Thrombolysis in Myocardial Infarc-
tion (TIMI)-II trial (31). Other investigators (32) have also
found the temporal pattern of myocardial ischemic episodes to
be similar between patients with and without diabetes. This
relation was lost only when patients with diabetes had moder-
ate to severe autonomic dysfunction. Whether these varied
reports represent differences in the patient groups, the extent
of autonomic dysfunction among the patients or reported
differences in prehospital aspirin use is uncertain.
Early mortality. The association of increased mortality
with diabetes mellitus has been observed in several thrombo-
lytic trials. Taken together (Table 6), with more than 80,000
pooled patients, mortality was at least 60% higher among
patients with diabetes than without. Despite differences in
baseline characteristics, diabetes mellitus is an important in-
dependent predictor of 30-day mortality (17) that is not
attributable to a larger infarct size (2,13,33–35). Indeed, in the
present study, we found that the median peak creatine kinase
level was lower among diabetic patients than nondiabetics
(1,281 vs. 1,445 IU/liter), despite the higher mortality associ-
ated with diabetes. Similarly, Stone et al. (13) reported that
early mortality was higher among patients with diabetes, even
though their peak creatine kinase levels were lower and their
global left ventricular ejection fractions similar to those of
nondiabetics. The discrepancy between global left ventricular
systolic function and survival after thrombolysis has been
observed by several investigators (36,37). Impairment of re-
gional left ventricular function in non–infarct-related areas
(which was more common among diabetic patients) (14,38)
and other factors intrinsic to diabetics, such as diastolic
dysfunction and myocardial fibrosis, may contribute to the
higher mortality.
Mortality is higher among diabetic patients treated with
insulin than among those who were not treated with insulin
(Table 6). The reason for this observation remains uncertain. It
may be partly accounted for by differences in metabolic
derangements, beyond glucose regulation, between non–
insulin-treated and insulin-treated diabetic patients. Further-
more, patients with more severe diabetes were probably more
likely to receive insulin treatment. Although animal models of
myocardial infarction have shown differences in infarct size
(39), metabolic activities (40) and possibly myocyte function
(41,42) between control animals and those with experimentally
induced diabetes, limited clinical data suggest that stringent
metabolic control may improve cardiovascular outcomes
(9,43).
Interaction with other coronary risk factors, such as age and
gender, may also affect mortality. Studies in both the pre-
thrombolytic (1,11,13) and thrombolytic (14,16) eras have
shown that mortality is considerably higher in women than in
diabetic men. In addition, duration of diabetes has also been
found to be associated with mortality (15,44). However, both
gender and duration of diabetes were not associated with
increased 30-day mortality after adjusting for other baseline
risk factors (17).
Other early clinical outcomes. The occurrence of stroke in
patients who have had a myocardial infarction not only limits
meaningful functional capacity, but also increases the risk for
subsequent early mortality (45). In contrast to previous trials
(14,15,46), patients with diabetes in the GUSTO-I cohort were
found more likely to have cerebrovascular events than nondia-
betics. The occurrence of stroke among patients with diabetes
was 1.9%, compared with 1.4% among patients without diabe-
tes (p , 0.001). This, too, is consistent with the prethrombo-
lytic era, where strokes, principally due to cerebral infarction,
occurred several-fold more frequently among diabetic (7.4%)
than nondiabetic (2.7%) patients (47). Pullicino et al. (47)
attributed this increase to concomitant cerebrovascular dis-
ease, co-existing risk factors, autonomic neuropathy leading to
postural hypotension and cardiogenic shock. It is interesting
that although the cerebrovascular event rate for nondiabetics
in the prethrombolytic era was comparable to that of the
GUSTO-I population, it was considerably higher among pa-
tients with diabetes. An important finding in our study is that
the incidence of primary intracranial hemorrhage or hemor-
rhagic conversion after cerebral infarction was not increased
among diabetic patients. This is corroborated by the report of
Table 6. Early Mortality and Diabetic Status in Randomized Trials
Study (ref no.) No. of Pts
30-Day Mortality Rate (%)
30-Day Mortality Rate (%)
Pts Without
Diabetes
Pts With
Diabetes OR (95% CI)*
Pts With Diabetes
OR (95% CI)†Non–Insulin Treated Insulin Treated
TAMI (14)‡ 1,071 5.7 11.5 2.04 (1.10–3.74) 10.7 15.0 148 (0.44–4.77)
ISG (15)‡ 8,055 7.5 12.7 1.79 (1.43–2.24) 11.8 16.9 1.52 (0.92–2.50)
GISSI-2 (16)‡ 11,667 7.3 12.3 1.82 (1.55–2.14) 11.7 16.4 1.49 (1.04–2.12)
FTT (21)§ 21,659 8.7 13.6 1.64 (1.43–1.87) NA NA NA
GUSTO-I\ 40,832 6.2 10.5 1.77 (1.61–1.95) 9.7 12.5 1.34 (1.11–1.60)
Pooled 83,284 7.1 11.6 1.71 (1.60–1.83) 10.4 13.5 1.34 (1.15–1.56)
*Patients (Pts) with versus without diabetes. †Insulin-treated versus non–insulin-treated diabetic patients. ‡In-hospital mortality. §35-day mortality. \30-day
mortality. CI 5 confidence interval; FTT 5 Fibrinolytic Therapy Trialists study; GISSI-2 5 Gruppo Italiano per lo Studio della Sopravvivenza nell’Infarto Micocardio;
GUSTO-I 5 Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries; ISG 5 International Tissue Plasminogen
Activator/Streptokinase Mortality trial; NA 5 not available; OR 5 odds ratio; ref 5 reference; TAMI 5 Thrombolysis and Angioplasty in Myocardial Infarction trial.
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the TIMI-II trial (48). Therefore, the risk of intracerebral
hemorrhage is not increased in patients with diabetes.
Consistent with previous reports (14,16), the rate of myo-
cardial reinfarction after thrombolysis was similar among
patients with and without diabetes. Although Barbash et al.
(15) found that the in-hospital reinfarction rate was higher in
patients with diabetes (4.9% vs. 3.8%) and at 6-month
follow-up (6.2% vs. 4.2%), in both instances, among their 883
patients, the association was lost with multivariable analysis.
Congestive heart failure after myocardial infarction is com-
mon in diabetic patients, particularly in those treated with
insulin (11). Despite a similar (35) or smaller (8) infarct size,
patients with diabetes are more likely to have heart failure than
nondiabetics. Interestingly, it is only among patients with a
moderate extent of myocardial injury that the association with
heart failure has been evident (8). These observations may be
related to factors associated with diabetes, such as impairment
of regional left ventricular function (14,38), maladaptation of
the autonomic system during hemodynamic stress, thickening
of the basement membranes leading to local tissue hypoxia
(49) and other metabolic derangements.
Although most studies (2,5,9,16) concur that atrioventricu-
lar block is more frequent among diabetic than nondiabetic
patients, the occurrence of ventricular tachycardia or fibrilla-
tion has been less consistent. Among our patients, onset of
ventricular fibrillation was not associated with diabetic status.
However, some reports (15,50) suggest that this arrhythmia is
more common among patients with diabetes. However, in a
recent observational study (51), ventricular fibrillation oc-
curred substantially less frequently among diabetic patients
treated with glibenclamide compared with diet or other oral
hypoglycemic agents.
Coronary angiography and revascularization. Patients
with diabetes in GUSTO were more likely to have multivessel
disease than patients without diabetes, which is consistent with
previous studies (14). Coronary artery disease in patients with
diabetes is generally more diffuse than in patients without
diabetes (14,52). These unfavorable anatomic features may
contribute to the increased morbidity and mortality among
diabetic patients. Preliminary results from the angiographic
substudy of the GUSTO-I population (53) showed that the
presence of TIMI flow grade 3 in the infarct-related artery at
90 min was similar among patients with and without diabetes
(41% vs. 38%). Likewise, the Thrombolysis and Angioplasty in
Myocardial Infarction (TAMI) study group (14) found that
there was no difference in 90-min patency rates (TIMI flow
grade 2 or 3) between patients with and without diabetes (71%
vs. 70%). Therefore, adverse outcome associated with patients
with diabetes cannot be purely related to early infarct artery
patency.
Despite the fact that patients with and without diabetes had
similar infarct-related artery patency rates, it is interesting to
note in the light of the recent preliminary report of the Bypass
Angioplasty Revascularization Investigation (BARI) (54) that
patients with diabetes in our study were more likely to undergo
bypass surgery than nondiabetics. This may be attributed to the
more frequent occurrence of diffuse, multivessel coronary
artery disease and marginally lower left ventricular ejection
fraction among those with diabetes.
Late mortality. Unlike most patients receiving thrombo-
lytic therapy, who demonstrate no survival benefit after the
first month (55–57), patients with diabetes continued to show
increased mortality compared with nondiabetics at late
follow-up (1-year). Although the development of thrombolytic
strategies and advancement of therapies for myocardial infarc-
tion appear to reduce early and late mortality for patients with
diabetes, their mortality remains 40% to 60% higher than that
for patients without diabetes (Fig. 3). Compared with nondia-
betics and non–insulin-treated diabetics, mortality among
insulin-treated patients remained highest during late follow-
up. These observations have been noted in previous studies at
intermediate follow-up (6-month) (15,16) (Fig. 3), and the
operating factors are probably intrinsic to diabetes.
Conclusions. In agreement with observations from previ-
ous studies (14–16), including TAMI and Gruppo Italiano per
lo Studio della Sopravvivenza nell’Infarto Miocardico (GISSI-
2), our results from the largest reported cohort of diabetic
patients (n 5 5,944) confirm that patients with diabetes have a
higher mortality at 30 days and 1 year, especially among those
treated with insulin. The OR for 30-day mortality for patients
with diabetes was 1.77 that of patients without diabetes. In
addition, we found that survival was improved in patients with
diabetes receiving accelerated t-PA compared with other
thrombolytic agents, which is consistent with the main results
from GUSTO-I. The rates for reinfarction were similar among
the different thrombolytic regimens. Unlike previous studies,
there was little interaction between diabetes and other risk
factors, and stroke occurred more frequently among diabetic
than nondiabetic patients. The incidence of intracranial hem-
orrhage was similar between patients with and without diabe-
Figure 3. Early (30 to 35 days) and late (6 to 12 months) mortality
among patients with and without diabetes. DM 5 patients with
diabetes; nonDM 5 patients without diabetes. ISG 5 International
Tissue Plasminogen Activator/Streptokinase Mortality trial (15).
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tes. Nonetheless, morbidity and mortality remain higher in
patients with diabetes than in those without it, even in the
contemporary thrombolytic era, despite correcting for differ-
ences in baseline clinical characteristics. To further improve
outcome after myocardial infarction and thrombolysis among
patients with diabetes, newer strategies such as peri-infarction
metabolic control (58) and primary angioplasty (59) should be
investigated.
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